Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiofronteraBFRI -1.84%35 Debt-to-Equity is 1.27 as of Mar. 2026, which is 606% above its 10-year median of 0.18. GuruFocus rates BFRI with a GF Score™ of 35/100 and a GF Value™ of $0.54 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 813 Drug Manufacturers companies, Biofrontera ranks worse than 90.28% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for Biofrontera's Debt-to-Equity or its related term are showing as below:
BFRI'
s Debt-to-Equity Range Over the Past 10 Years
Min: -1.9 Med: 0.18 Max: 10.37
Current: 1.27
During the past 7 years, the highest Debt-to-Equity Ratio of Biofrontera was 10.37. The lowest was -1.90. And the median was 0.18.
BFRI's Debt-to-Equity is ranked worse than 90.28% of 813
companies
in the Drug Manufacturers industry
Industry Median: 0.27
vs BFRI: 1.27
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
Biofrontera Debt-to-Equity Related Terms
Biofrontera Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for Biofrontera's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
BFRI vs HYEX, CABR, IGPK: Debt-to-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Biofrontera's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biofrontera Debt-to-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Biofrontera's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where Biofrontera's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biofrontera (BFRI) has a Debt-to-Equity of 1.27 as of Mar. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biofrontera and its competitors. This is 606% above median its historical median of 0.18. According to the industry distribution chart, Biofrontera ranks #734 out of 813 companies in the Drug Manufacturers industry, placing it in the top 90.3%.
Is Biofrontera's Debt-to-Equity too high?
Biofrontera's current Debt-to-Equity of 1.27 is 606% above median its 10-year median of 0.18. The Drug Manufacturers industry median Debt-to-Equity is 0.27. Biofrontera's value of 1.27 is 370.4% above this industry median. Based on the distribution chart, Biofrontera ranks #734 out of 813 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Biofrontera has a GF Score™ of 35/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Biofrontera's Debt-to-Equity compare to HYEX and CABR?
According to the Drug Manufacturers industry distribution chart, Biofrontera ranks #734 out of 813 companies for Debt-to-Equity. This places Biofrontera in the lower half of its industry. The industry median Debt-to-Equity is 0.27. Biofrontera's value of 1.27 is 370.4% above this benchmark. While the company's 10-year median is 0.18 vs. the industry median of 0.27, Biofrontera has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Drug Manufacturers company?
The median Debt-to-Equity among Drug Manufacturers companies is 0.27, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biofrontera's current Debt-to-Equity of 1.27 is 370.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on Biofrontera and its competitors. For the Drug Manufacturers industry, the median Debt-to-Equity is 0.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biofrontera's current Debt-to-Equity is 1.27, which is 606% above median its own 10-year median of 0.18. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biofrontera stock overvalued right now?
Based on GuruFocus' analysis, Biofrontera (BFRI) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.54, compared to a current price of $1.07 — trading 97.2% above its estimated fair value. The current Debt-to-Equity is 1.27, which is 606% above median its 10-year median of 0.18 and 370.4% above the Drug Manufacturers industry median of 0.27. Biofrontera's overall GF Score™ is 35/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For Biofrontera (BFRI), the current Debt-to-Equity is 1.27 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biofrontera (BFRI) Overvalued in 2026?
Based on GuruFocus' analysis, Biofrontera stock appears to be overvalued.
The current stock price of $1.07 is trading 97.2% above its estimated GF Value™ of $0.54.
GuruFocus considers Biofrontera to be Significantly Overvalued.
Key valuation signals for BFRI:
Debt-to-Equity: 1.27 (606% above median its 10-year median of 0.18)
GF Value™: $0.54 vs. price of $1.07 (97.2% above fair value)
Industry Position: 370.4% above the Drug Manufacturers median (#734 of 813)
No single metric tells the full story. See the BFRI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Biofrontera Inc is a United States-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy. The Company's licensed products, which include Ameluz as well as the BF-RhodoLED and RhodoLED XL lamps (together, the RhodoLED Lamps), are used for the treatment of actinic keratoses (AKs), which are pre-cancerous skin lesions. The company's revenues are derived from within the United States and, therefore, no other geographical segments.
35GF Score
Get the complete analysis for BFRI
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BFRI has been successfully added to your 
